Abstract
Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new group of immune-related adverse events (irAEs) in almost any organ system. Among these irAEs, rheumatic complications are common and seem to have features that are distinct from irAEs in other organ systems, including a highly variable time of clinical onset and the capacity to persist, possibly indefinitely, even after cessation of CPI therapy. In this Review, mechanisms of action of CPIs and how they might cause rheumatic irAEs are described. Also covered are epidemiology and clinical descriptions of rheumatic irAEs, plus guiding principles for managing irAEs. Finally, we outline future directions that must be taken in response to a series of unanswered questions and unmet needs that now confront rheumatologists who are, or will be, engaged in this new area of rheumatology.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 569-579 |
| Number of pages | 11 |
| Journal | Nature Reviews Rheumatology |
| Volume | 14 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Rheumatology
Cite this
Rheumatic immune-related adverse events from cancer immunotherapy. / Calabrese, Leonard H.; Calabrese, Cassandra; Cappelli, Laura.
In: Nature Reviews Rheumatology, Vol. 14, No. 10, 01.10.2018, p. 569-579.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Rheumatic immune-related adverse events from cancer immunotherapy
AU - Calabrese, Leonard H.
AU - Calabrese, Cassandra
AU - Cappelli, Laura
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new group of immune-related adverse events (irAEs) in almost any organ system. Among these irAEs, rheumatic complications are common and seem to have features that are distinct from irAEs in other organ systems, including a highly variable time of clinical onset and the capacity to persist, possibly indefinitely, even after cessation of CPI therapy. In this Review, mechanisms of action of CPIs and how they might cause rheumatic irAEs are described. Also covered are epidemiology and clinical descriptions of rheumatic irAEs, plus guiding principles for managing irAEs. Finally, we outline future directions that must be taken in response to a series of unanswered questions and unmet needs that now confront rheumatologists who are, or will be, engaged in this new area of rheumatology.
AB - Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new group of immune-related adverse events (irAEs) in almost any organ system. Among these irAEs, rheumatic complications are common and seem to have features that are distinct from irAEs in other organ systems, including a highly variable time of clinical onset and the capacity to persist, possibly indefinitely, even after cessation of CPI therapy. In this Review, mechanisms of action of CPIs and how they might cause rheumatic irAEs are described. Also covered are epidemiology and clinical descriptions of rheumatic irAEs, plus guiding principles for managing irAEs. Finally, we outline future directions that must be taken in response to a series of unanswered questions and unmet needs that now confront rheumatologists who are, or will be, engaged in this new area of rheumatology.
UR - http://www.scopus.com/inward/record.url?scp=85053302057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053302057&partnerID=8YFLogxK
U2 - 10.1038/s41584-018-0074-9
DO - 10.1038/s41584-018-0074-9
M3 - Review article
C2 - 30171203
AN - SCOPUS:85053302057
VL - 14
SP - 569
EP - 579
JO - Nature reviews. Rheumatology
JF - Nature reviews. Rheumatology
SN - 1759-4790
IS - 10
ER -